Therapeutic Classes/Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor
Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor
33 drugs across 16 manufacturers|25 Generic,8 Brand
Total Drugs
33
25G / 8B
Manufacturers
16
Avg $25.0508/unit
Avg 7d Change
+1.12%
Across 20 drugs with changes
7d Activity
10↑10↓13 flat
of 33 total drugs
Class Price Trend
Monthly average NADAC price per unit, split by generic and brand
Manufacturer Breakdown
16 manufacturers producing drugs in this therapeutic class(2 pricing outliers)
Mylan Pharmaceuticals Inc.
3 drugs
$38.8855
avg/unit
Janssen Products LP
3 drugs
$27.7757
avg/unit
Macleods Pharmaceuticals Limited
3 drugs
$0.9600
avg/unit
Camber Pharmaceuticals Inc.
3 drugs
$0.9273
avg/unit
Aurobindo Pharma Limited
3 drugs
$0.9220
avg/unit
Gilead Sciences, Inc.
High Outlier
2 drugs
$130.4347
avg/unit
Merck Sharp & Dohme LLC
2 drugs
$76.9320
avg/unit
Patriot Pharmaceuticals
2 drugs
$9.5452
avg/unit
Amneal Pharmaceuticals NY LLC
2 drugs
$9.5452
avg/unit
Leading Pharma, LLC
2 drugs
$9.5452
avg/unit
Bionpharma Inc.
2 drugs
$9.5452
avg/unit
Cipla USA Inc.
2 drugs
$1.3173
avg/unit
and 4 more manufacturers